NCT03863145View on ClinicalTrials.gov

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

June 1, 2026

Conditions
Advanced Refractory Solid TumorsSubjects Considered Likely to Respond to CB-03-10
Interventions
DRUG

CB-03-10

CB-03-10, 100 mg capsule for oral use

Trial Locations (6)

44718

RECRUITING

Gabrail Cancer Center, Ohio City

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Michigan Center

77598

RECRUITING

Tranquil Clinical Research, Texas City

80045

RECRUITING

University of Colorado Cancer Center, Colorado Springs

92868

RECRUITING

University of California Irvine Health Chao Family Comprehensive Cancer Center, California City

208028

RECRUITING

Yale Cancer Center, New Haven

Sponsors
All Listed Sponsors
lead

Cosmo Technologies Ltd

INDUSTRY

NCT03863145 - Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter